| Kimmtrak (tebentafusp-tebn) / Immunocore |
| Not yet recruiting | 3 | 290 | NA | Tebentafusp | European Organisation for Research and Treatment of Cancer - EORTC, Northwell Health, Immunocore Ltd | Uveal Melanoma | 11/32 | 11/32 | | |
TEBE-AM, NCT05549297: Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma |
|
|
| Recruiting | 2/3 | 460 | Europe, US, RoW | Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice | Immunocore Ltd | Advanced Melanoma | 12/26 | 09/27 | | |
| Active, not recruiting | 2 | 378 | Europe, Canada, US, RoW | IMCgp100, Dacarbazine, DTIC-Dome, DTIC, DIC, Imidazole Carboxamide, Ipilimumab, Yervoy, Pembrolizumab, Keytruda | Immunocore Ltd | Uveal Melanoma | 10/20 | 06/25 | | |
NCT06627244: Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma |
|
|
| Not yet recruiting | 2 | 30 | US | Tebentafusp, Tebentafusp-tebn, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization, Y-90 TARE | University of Miami, Immunocore Ltd | Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | 12/27 | 12/30 | | |
| Not yet recruiting | 2 | 19 | US | Tebentafusp-Tebn | Thomas Jefferson University | Locally Advanced Unresectable Uveal Melanoma | 10/25 | 04/29 | | |
| Recruiting | 2 | 850 | Europe | Tebentafusp, IMCgp100 | University of Oxford, Immunocore Ltd, Natera, Inc. | Melanoma (Skin), Melanoma, Uveal | 06/25 | 06/26 | | |
NCT06070012: Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma |
|
|
| Not yet recruiting | 2 | 44 | US | Tebentafusp, Kimmtrak | Diwakar Davar, Immunocore Ltd | Uveal Melanoma | 10/26 | 10/29 | | |
| Completed | 1/2 | 146 | Europe, Canada, US | IMCgp100, Tebentafusp, Kimmtrak | Immunocore Ltd | Uveal Melanoma | 03/20 | 10/22 | | |
| Withdrawn | 1/2 | 113 | US | Tebentafusp (IMCgp100) | Immunocore Ltd, AstraZeneca | Malignant Melanoma | 06/23 | 09/23 | | |
|
| Recruiting | 1/2 | 727 | Europe, Canada, US, RoW | Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors | Immunocore Ltd | Select Advanced Solid Tumors | 02/26 | 08/26 | | |
| Not yet recruiting | 1/2 | 109 | US | Tebentafusp-Tebn, kimmtrak, IMCgp100, GM-CSF (Sargramostim), yeast-derived recombinant human GM-CSF, Leukine, Hepatic Immunoembolization, GM-CSF, Sargramostim, BCNU, Carmustine, BiCNU, bis-chloroethylnitrosourea, Hepatic Chemoembolization, 1,3-bis [2-chloroethyl]-1-nitrosourea | Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University | Metastatic Uveal Melanoma | 07/26 | 08/26 | | |
NCT04960891: A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp |
|
|
| Available | N/A | | NA | Tebentafusp | Immunocore Ltd, Clinigen, Inc. | Uveal Melanoma | | | | |
| SCIB1 / Scancell |
2018-002844-10: Study of SCIB1 in melanoma (skin cancer) patients receiving pembrolizumab |
|
|
| Not yet recruiting | 2 | 25 | Europe | SCIB1, SCIB1, Solution for injection | Scancell Ltd, Scancell Ltd | Advanced unresectable melanoma., Skin cancer that cannot be surgically removed., Diseases [C] - Cancer [C04] | | | | |
SCOPE, NCT04079166: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The Study) |
|
|
| Recruiting | 2 | 130 | Europe | SCIB1 or iSCIB1+ DNA vaccine | Scancell Ltd | Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV | 01/26 | 01/26 | | |
| ALVAC gp100 / Sanofi |
| No trials found |
| PDC*mel / PDC line Pharma |
| No trials found |
| MIP3α-Gp100-Trp2 DNA vaccine / Johns Hopkins Bloomberg School of Public Health |
| No trials found |
